Summary of Research: Immunogenicity of Adalimumab Reference Product and Adalimumab-adbm in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis: A Pooled Analysis of the VOLTAIRE trials
Abstract This summary-of-research article presents the findings of a post hoc analysis comparing immunogenicity across the VOLTAIRE trials program, originally published in BMJ Open. Adalimumab-adbm (Cyltezo®) is approved by the US Food and Drug Administration as an interchangeable biosimilar to the...
Sábháilte in:
| Príomhchruthaitheoir: | |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Adis, Springer Healthcare
2025-06-01
|
| Sraith: | Rheumatology and Therapy |
| Ábhair: | |
| Rochtain ar líne: | https://doi.org/10.1007/s40744-025-00766-6 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|